Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saved in:
| Title: | Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. |
|---|---|
| Authors: | Saif MW; Tufts Cancer Center - Medical Center, Tufts University School of Medicine, 800 Washington St., Ste. 7099, 7-South, Boston, MA, 02111, USA. wsaif@tuftsmedicalcenter.org., Knost JA; Illinois CancerCare, Peoria, IL, USA., Chiorean EG; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kambhampati SR; Eli Lilly and Company, Bridgewater, NJ, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Pytowski B; Eli Lilly and Company, New York, NY, USA., Qin A; Eli Lilly and Company, Bridgewater, NJ, USA., Kauh JS; Eli Lilly and Company, Bridgewater, NJ, USA., O'Neil BH; Indiana University, Indianapolis, IN, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Oct; Vol. 78 (4), pp. 815-24. Date of Electronic Publication: 2016 Aug 26. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
